XIIIHIV/HCV共感染者での抗HIV療法

文献

  1. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV coinfection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 16: 797-808. 2106.
  2. Nijmeijer BM, Sarrami-Forooshani R, Steba GS, et al. HIV-1 exposure and immune activation enhance sexualtransmission of Hepatitis C virus by primary Langerhans cells J Int AIDS Soc 22:e25268, 2019.
  3. Hoornenborg E, Coyer L, Boyd A,et al. High incidence of HCV in HIV-negative men who have sex with men using preexposure prophylaxis. J Hepatol 2019. Epub. https://www.journal-of-hepatology.eu/article/S0168-8278(19)30719-6/fulltext
  4. Ramière C, Charre C, Miailhes P, et al. Patterns of hepatitis C virus transmission in human immunodeficiency virus (HIV)-infected and HIV-negative men who have sex with men. C Infect Dis 69; 2127-35, 2019.
  5. Bartlett SR, Wertheim JO, Bull RA, et al. A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. J Viral Hepat. 24:404?11. 2017.
  6. Centers for Disease Control and Prevention. Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men - New York City, 2005-2010. Morb Mortal Wkly Rep. 60:945-50. 2011.
  7. Foster AL, Gaisa MM, Hijdra RM, et al. Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis. 64:284-88. 2016.
  8. Nishijima T, Shimbo T, Komatsu H, et al. Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo. J Acquir Immune Defic Syndr. 65(2):213-7. 2014.
  9. Nguyen T, Delaugerre C, Valantin MA, et al. Shared HCV transmission networks among HIV-1-positive and HIV-1-negative men having sex with men by ultradeep sequencing. J AIDS 82; 105-110, 2019.
  10. Irvin R, Gamble T, Malone J, et al. HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status. Clin Infect Dis. 2020 Dec 21: ciaa1869. doi: 10.1093/cid/ciaa1869. Online ahead of print.
  11. 小池和彦 HIV感染症に合併する各種疾病に関する研究.厚生労働科学研究費補助金エイズ対策研究事業 平成19年度総括・分担研究報告書.
  12. Koike K, Tsukada K, Yotsuyanagi H, et al. Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res. 37:2-5. 2007.
  13. Tatsunami S, Mimaya J, Shirahata A, et al. Current status of Japanese HIV-infected patients with coagulation disorders: coinfection with both HIV and HCV. Int J Hematol. 88:304-10. 2008.
  14. Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 59:45-51. 2013.
  15. Lambers FA, Prins M, Thomas X, et al. Alarming incidence of HCV re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV MSM. AIDS. 25:F21-7. 2011.
  16. Sarrazin C, Isakovv V, Svarovskaia ES, et al. Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis. 64:44-52. 2017.
  17. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 13:34-41. 2006.
  18. Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 197:1558-66. 2008.
  19. Dionne-Odom J, Osborn MK, Radziewicz H, et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis. 9:775-83. 2009.
  20. Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 3:e492. 2006.
  21. Kokordelis P, Krämer B, Körner C, et al. An effective interferon-gamma mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology. 59:814-27. 2014.
  22. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 48:418-31. 2008.
  23. Stenkvist J, Nystr?m J, Falconer K, et al. Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. J Hepatol. 61:957-61. 2014.
  24. Vispo E, Barreiro P, Plaza Z, et al. Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. AIDS. 28:1473-8. 2014.
  25. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 32:492-7. 2001.
  26. HCV in HIV: Challenges and Opportunities. The PRN NOTEBOOK. 6:14-18. 2001.
  27. Fujinaga H, Tsutsumi T, Yotsuyanagi H, et al. Hepatocarcinogenesis in Hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species. Oncology. 81(suppl 1): 11-17. 2011.
  28. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 43:365-72. 2006.
  29. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 44:1026-32. 2006.
  30. Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood. 105:1170-8. 2005.
  31. Pembroke T, Deschenes M, Lebouch? B, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV coinfected patients and is associated with liver fibrosis. J Hepatol. 67:801-8. 2017.
  32. Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus. Gastroenterology. 140:809-17. 2011.
  33. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 30:1054-8. 1999.
  34. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 21:2209-16. 2007.
  35. Martinez-Sierra C, Arizcorreta A, Díaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis.36:491-8. 2003.
  36. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol. 55:756-61.2011.
  37. Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-β1-dependent manner. Gastroenterology. 134: 803-11. 2008.
  38. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/ hepatitis C virus-induced liver fibrosis. Hepatology. 52: 612?22. 2010.
  39. Seki E, Minicis S, Ӧsterreicher C, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med.13: 1324?32. 2007.
  40. Lidofsky A, Holmes JA, Feeney ER, et al. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis. 218:1394-1403. 2018.
  41. Chen X, Liu X, Duan S, et al. Plasma Inflammatory Biomarkers Associated with Advanced Liver Fibrosis in HIV-HCVCoinfected Individuals. Int J Environ Res Public Health. 17:9474, 2020.
  42. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U. S.-Canadian multicenter study. J Hepatol. 47:527-37. 2007.
  43. Salmon D, Bani-Sadr F, Loko MA, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH. J Hepatol. 56:862-8. 2012.
  44. Thein HH, Yi Q, Dore GJ, and Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS. 22:1979-91. 2008.
  45. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 44: 47?55. 2006.
  46. Sherman KE, Andersen JW, Butt AA, et al. Sustained long-term antiviral maintenance therapy in HCV/HIV-Coinfected patients (SLAM-C). J Acquir Immune Defic Syndr. 15: 597-605. 2010.
  47. Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol. 8: 1070?6. 2010.
  48. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 63: 1160-7. 2016.
  49. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis.33:240-7. 2001.
  50. Yoo TW, Donfield S, Lail A, et al. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis. 191:4-10. 2005.
  51. Daar ES, Lynn H, Donfield S, et al. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis. 183:589-95. 2001.
  52. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 36:363-7. 2003.
  53. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis. 32:1207-14. 2001.
  54. Haydon GH, Flegg PJ, Blair CS, et al. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol.10:485-9. 1998.
  55. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA. 288:199-206. 2002.
  56. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 192:992-1002. 2005.
  57. Kovari H, Rauch A, Kouyos R, et al. Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIVpositive persons in the Swiss HIV Cohort Study. Clin Infect Dis. 64:490-7. 2016.
  58. Meijide H, Pertega S, Rodríguez-Osorio I, et al. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS. 31:1099?107. 2017.
  59. Alejos B, Hernando V, Iribarren J, et al. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection. Medicine (Baltimore). 95: e4727. 2016.
  60. Tan BK, Chalouni M, Ceron DS, et al. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clin Infect Dis. 2020 Jul 20:ciaa1014. doi: 10.1093/cid/ciaa1014. Online ahead of print.
  61. Carrero A, Berenguer J, Hontañón V, et al. Effects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patients. Clin Infect Dis. 2020 Sep 15:ciaa1396. doi: 10.1093/cid/ciaa1396. Online ahead of print.
  62. H Al-Mohri, T Murphy, Y Lu, et al. Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker. J Acquir Immune Defic Syndr. 44:463-9. 2007.
  63. Berenguer J, Zamora FX, Aldamiz-Echevarria T, et al. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 60:950-8. 2015.
  64. Macías J,Girón-González JA, González-Serrano M, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut. 55:409-14. 2006.
  65. Sánchez-Conde M, Montes-Ramírez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 17:280?6. 2010.
  66. Sánchez-Conde M, Miralles P, Bell?n JM, et al. Use of transient elastography (FibroScan) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients. J Viral Hepat. 18:685?91. 2011.
  67. Ichikawa S, et al. Magnetic Resonance Elastography for Staging Liver Fibrosis in Chronic Hepatitis C. Magn Reson Med Sci. 2013; 11: 291-97.
  68. Sherman, KE, Abdel-Hameed, EA, Ehman, RL, Rouster, SD, Campa, A, Martinez, SS, Huang, Y, Zarini, GG, Hernandez, J, et al. Validation and Refinement of Noninvasive Methods to Assess Hepatic Fibrosis: Magnetic Resonance Elastography Versus Enhanced Liver Fibrosis Index. Dig Dis Sci 2019. https://link.springer.com/article/10.1007/s10620-019-05815-z
  69. Okanoue T, Itoh Y, Minami M, et al. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res. 38:27-36. 2008.
  70. Maida I, Soriano V, Barreiro P, et al. Liver fibrosis stage and HCV genotype distribution in HIV-HCV co-infected patients with persistently normal transaminases. AIDS Res Hum Retroviruses. 23:801-4. 2007.
  71. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr. 41:63?7. 2006.
  72. Perez-Olmeda M, Garcia-Samaniego J, Soriano V, et al. Hepatitis C viremia in HIV/HCV-coinfected patients having immune restoration with highly active antiretroviral therapy. AIDS. 14:212. 2000.
  73. Asmuth DM, Busch MP, Laycock ME, et al. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Antiviral Res. 63:123-31. 2004.
  74. Kottilil S, Jagannatha S, Lu A, et al. Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. HIV Clin Trials. 5:25-32. 2004.
  75. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS.16:1915-23. 2002.
  76. Benhamou Y, DeMartinio V, Bochet M, et al. factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients: impact of protease inhibitor therapy. Hepatology. 34:283-7. 2001.
  77. Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV co-infection on the risk of cirrhosis and hepatocellular carcinoma. In U.S. veterans with hepatitis C. Am J Gastroenterol. 100:56-63. 2005.
  78. Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 44:47-55. 2006.
  79. Qurishi N, Kleuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 362:1708-13. 2003.
  80. Ragni MV, Nalesnik MA, Schillo R, et al. Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV coinfection. Haemophilia. 15:552-8. 2009.
  81. Tedaldi EM, Baker RK, Moorman AC, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 36: 363-7. 2003.
  82. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology.41: 123-31. 2005.
  83. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283:74-80. 2000.
  84. Montaner JS, Hogg R, Raboud J, et al. Antiretroviral treatment in 1998. Lancet. 352:1919-22. 1998.
  85. Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet. 352:821-2. 1998.
  86. Brunet L, Moodie EE, Young J, et al. Progression of liver fibrosis and modern combination antiretroviral therapy regimens in HIV-hepatitis C-coinfected persons. Clin Infect Dis. 62: 242-9. 2016.
  87. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C co-infection. Clin Infect Dis. 38(suppl 2): S104-S108. 2004.
  88. Atranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 40: 588-93. 2005.
  89. Avidan NU, Goldstein D, Rozenberg L, et al. Hepatitis C viral kinetics during treatment with Peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr. 52: 452-8. 2009.
  90. Rozera G, FabbriG, Lorenzini P, et al. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. Plos one.12(10):e0187095. 2017.
  91. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 15: 645-53. 2015.
  92. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 370: 1889-98. 2014.
  93. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-88. 2014.
  94. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 370: 1483-93. 2014.
  95. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 313: 1232-9. 2015.
  96. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 373: 705-13. 2015.
  97. Nagao A, Hanabusa H. The impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr. 74:418-22. 2016.
  98. Uemura H, Tsukada K, Mizushima D, et al. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders. Plos one. 12 (10) e0186255. 2017.
  99. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 385:1087-97. 2015.
  100. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO -INFECTION): a non-randomised, open-label trial. Lancet HIV. 2: e319-27. 2015.
  101. Braun DL, Hampel B, Kouyos R, et al. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. Clin Infect Dis. 2018 Aug 13. doi: 10.1093/cid/ciy547.).
  102. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 59: 2403-12. 2014.
  103. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 33: 106-15. 2000.
  104. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a metaanalysis of individual patient data. Gastroenterology.130:1636-1642. 2006.
  105. Bochud P-Y, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 51: 655-6. 2009.
  106. Probst A, Dang T, Bochud M, et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and metaanalysis. J Viral Hepatitis. 18: 745-59. 2011.
  107. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatitis. 18: e516-e522. 2011.
  108. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-93. 2012.
  109. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 28: 397-404. 2008.
  110. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 54: 789-800. 2011.
  111. 萩原 剛、四柳 宏、藤井輝久ら. HIV合併を含む血友病患者におけるC型慢性肝炎のDAA治療において保険適応外となるHCVジェノタイプに対する治療の試み. 日本エイズ学会誌. 19:462, 2017.
  112. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 17: 1062-8. 2017.
  113. Wyles D, Poordad F, Wang S, et al. Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial. Hepatology. 67: 514-23. 2018.
  114. Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 67 :1010-7. 2018.
  115. Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 67:263-271, 2017.
  116. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 17:1062-1068, 2017.
  117. Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 67:1010-1017, 2018.
  118. Izumi N, Takehara T, Chayama K, et sl. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int.12:356-367, 2018.
  119. Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCVinfected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 54:87-95, 2019.
  120. Montes ML, Olveira A, Ahumada A, et al. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS. 31:1253?60. 2014.
  121. Shafran SD. HIV coinfected have similar SVR rates as HCV mono-infected with DAAs: it's time to end segregation and integrate HIV patients into HCV trials. Clinical infectious diseases. 61: 1127-34. 2015.
  122. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 166:792-8. 2017.
  123. Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 15:132-6. 2017.
  124. Schwabl P, Mandorfer M, Steiner S, et al. Interferon free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 45: 139-49. 2017.
  125. Rial-Crestelo D, Sepúlveda M, González-Gasca F, et al. Does fibrosis really regress in HIV/HCV co-infected patients after treatment with direct-antiviral agents? AIDS. 34(3): 427-432. 2020 epub DOI: 10.1097/QAD.0000000000002433.
  126. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol. 30: 653-9. 1999.
  127. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 87: 741-9. 2000.
  128. Takimoto M, Ohkoshi S, Ichida T, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci. 47: 170-6. 2002.
  129. Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 23: 593-6. 2003.
  130. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 67:1204-12. 2017.
  131. Merchante N, Rivero-Juarez A, Telletz F, et al. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. J Antimicrob Chemother. 73 :2435-43. 2018.
  132. Salmon-Ceron D, Nahon P, Layese R, et al. HIV/HCV co-infected cirrhotic patients are no longer at higher risk for HCC or endstage liver disease as compared to HCV mono-infected patients. Hepatology. 2018 Dec 19. doi: 10.1002/hep.30400. [Epub ahead of print]).
  133. 日本肝臓学会.C型肝炎治療ガイドライン(第6版https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c.html)p4.
  134. Hasson H, Merli M, Messina E, Bhoori S, Salpietro S, Morsica G, Regalia E, Bagaglio S, Lazzarin A, Uberti-Foppa C, Mazzaferro V. Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. J Hepatol. 67: 415-7. 2017.
  135. Carrieri MP, Protopopescu C, Marcellin F, et al. Protective effect of coffee consumption on all-cause mortality of French HIVHCV co-infected patients. J Hepatol. 67:1157-67. 2017.
  136. Barre T, Protopopescu C, Bani-Sadr F, et al. Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH cohort study). Hepatology epub. https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30914
  137. Santos ME, Protopopescu C, Sogni P, et al. HCV-related mortality among HIV/HCV co-infected patients: the importance of behaviors in the HCV cure era (ANRS CO13 HEPAVIH Cohort). AIDS Behav (2019). https://doi.org/10.1007/s10461-019-02585-7
  138. Ghiglione Y, Polo ML, Urioste A, et al. Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. Open Forum Infect Dis. 2020 2;7:ofaa115.
  139. Carrero A, Berenguer J, Hontañón V, et al. Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr. 2020;83:292-300.
  140. Chalouni M, Pol S, Sogni P, et al. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. J Hepatol. 2021;74:37-47.

PAGE TOP

アンケートにご協力ください。

このページは役に立ちましたか?

コメント